If designed as a controlled release dosage form, the dosage form of the present invention may be an osmotic dosage form.

The composition may be used as a component of a pharmaceutical dosage form, such as the shell of a dosage form, or as an edible matrix, i.e., a pharmaceutical dosage form per se.

The composition may be used as a component of a pharmaceutical dosage form, such as the shell of a dosage form, or as an edible matrix, i.e., a pharmaceutical dosage form per se.

In certain embodiments, the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.

The present invention is also directed toward methods of making the dosage form, methods of using the dosage form, and kits comprising the dosage form.

Said composition is a reservoir type form or a matricial type form.

The novel dosage form may be in a form of a coated tablet or multi- unit dosage form comprising coated particles.

The dosage form can then be formulated.

It further relates to a method of preparing the same and to a container comprising the dosage form.

Methods for preparation of the dosage form, and methods for use of the dosage form, are also provided.

The surface roughness parameters of a first dosage form are determined and compared to the surface roughness parameters of a second dosage form.

Particularly, the invention relates to a pharmaceutical dosage form wherein the dosage form is in a powder form and is contained in a pharmaceutically acceptable capsule.

The present invention relates to a pharmaceutical dosage form, and methods and system for making the pharmaceutical dosage form.

More particularly, the invention relates to a pharmaceutical dosage form of selective COX-2 inhibitors wherein the dosage form can be administered intramuscularly.

This invention relates to a dosage form of cabozantinib and a method of employing the dosage form to treat cancer.